StockData
Renalytix plc logo

Renalytix plc (RNLXY) stock

RNLXYOTCServices-Medical LaboratoriesFiscal year ends June 30Also trades as RENXF
Số liệu tài chính tới Q1 năm tài chính 2025, quý kết thúc ngày Sep 30, 2024Last filing: 10-Q on Nov 19, 2024
$3.56+0.06 (+1.57%)

Close on Oct 19, 2026Market cap $375.75MP/E –Yield –

Renalytix plc saw revenue fall 18.7% to $2.35M over the twelve months to Sep 30, 2024. At the latest close the market valued the company at $375.75M.

Revenue
$2.35M
-18.7% vs. a year earlier
Operating income
-$24.81M
TTM Q1 2025
EPS, diluted
-$0.26
TTM Q1 2025

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2024

Valuation

Market cap
$375.75M
P/E ratio
–
Price to sales
159.76
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Revenue
$2.35M
Net income
-$28.03M
EPS, diluted
-$0.26
Book value per share
-$0.11
Diluted shares
106M

Trading

Previous close
$3.50
Open
$3.58
Day's range
$3.56 – $3.58
Volume
2,860
Average volume (20 days)
4,937

Market cap history

Month-end market cap since 2020, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodRNLXYS&P 500DifferenceRNLXY per yearS&P 500 per year
1 month-14.3%+0.6%−15.0 pts
3 months+92.2%+3.4%+88.8 pts
Year to date-1.8%+13.3%−15.1 pts
1 year-97.9%+16.6%−114.5 pts
3 years-99.6%+86.4%−185.9 pts-83.7%+23.1%
5 years-100.0%+81.9%−181.8 pts-81.2%+12.7%

Seven years at a glance

Fiscal years 2018 to 2024 and trailing twelve months, USD

Revenue

$2.35M-18.7% YoY

Gross profit

$299.00K-26.0% YoY

Operating income

-$24.81M

Net income

-$28.03M

EPS, diluted

-$0.26

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Renalytix filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Renalytix

Services-Medical Laboratories

Renalytix plc is an in vitro diagnostics company focused on managing kidney disease through artificial intelligence-enabled prognostic tools. The company develops and provides diagnostic services designed to assess the risk of progressive kidney function decline in adults with type 2 diabetes and early-stage chronic kidney disease. Its core offering, kidneyintelX.dkd, combines blood biomarkers with clinical algorithms to assist clinicians in identifying individuals who require early medical intervention before major organ damage occurs. The company markets its diagnostic testing services primarily to healthcare providers, primary care physicians, and clinical networks across the healthcare sector.

Company profile, executives and history

Renalytix stock: common questions

What is Renalytix's stock price?

RNLXY closed at $3.56 on Oct 19, 2026, up 1.57% on the day.

What is Renalytix's market cap?

Renalytix was worth $375.75M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is RNLXY's P/E ratio?

Renalytix lost money over the twelve months to Sep 30, 2024 (diluted EPS -$0.26), so it has no meaningful P/E ratio.

How much revenue does Renalytix make?

Renalytix reported revenue of $2.35M for the twelve months to Sep 30, 2024, down 18.7% from a year earlier.

Does Renalytix pay a dividend?

No. Renalytix has not paid a cash dividend over the last twelve months.

How has RNLXY stock performed over the past year?

Including dividends, RNLXY returned -97.9% over the past year, against +16.6% for the S&P 500.

Who are Renalytix's competitors?

Companies most similar to Renalytix by business, industry and size include SERA, XGN, CDNA, MDXH, BDSX.

See a number that looks wrong?